Canaccord Genuity’s $13 target on ACHV

ACHV Achieve Life Sciences

$7.25 → $13 (+79%) by Aug 2027

Buy · reiterates · said Aug 13, 2026 · 12-month default horizon

Open: judged on the close on Aug 13, 2027

The article this target came from

Morgan Stanley initiates Achieve Life Sciences stock at overweight

Investing.com · Aug 13, 2026

Canaccord Genuity also reiterated a Buy rating with a $13.00 price target

Canaccord Genuity’s track record → Achieve Life Sciences →

A fact about what Canaccord Genuity published, as reported by Investing.com, not a recommendation from Dalsna Finance; Canaccord Genuity is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.